T-knife Therapeutics
T-knife Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at T-knife Therapeutics.
T-knife Therapeutics is a company.
Key people at T-knife Therapeutics.
Key people at T-knife Therapeutics.
T-knife Therapeutics is a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-Ts) for solid tumors, leveraging proprietary platforms to create "supercharged" T cells for deeper, more durable responses.[1][2][3] It targets high-unmet-need indications like PRAME-expressing cancers with its lead candidate TK-6302, planning a Clinical Trial Application (CTA) in Q4 2025 and Phase 1 trial in 2026, serving patients with difficult-to-treat solid tumors where current therapies fall short.[2][3] The company's growth momentum includes a robust pipeline from its MyT™ discovery platform, international investor backing (e.g., Andera Partners, EQT Life Sciences, RA Capital, Versant Ventures), and recent data presentations at ESGCT 2025 showcasing novel targets.[1][2]
T-knife was founded by leading T-cell and immunology experts using technology from the Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin in Germany.[1][2] The idea emerged from advancing TCR discovery and T cell engineering to address solid tumor challenges, with the company establishing in the life sciences sector around 2021, marked by EQT's entry via LSP 6 fund.[5] Early traction built on the proprietary MyT™ platform for *in vivo*-selected, tumor-specific TCRs, complemented by novel CD8 coreceptors and switch receptors; leadership includes Thomas Soloway (ex-Audentes COO, Ascendis CFO) driving operations.[1]
T-knife rides the T cell therapy wave in oncology, shifting from CAR-T (liquid tumors) to TCR-T for solid tumors, where antigen heterogeneity and immunosuppression demand precise, armored cells.[1][3][4] Timing aligns with maturing synthetic biology and multi-omics tools, accelerating discovery amid surging demand for durable solid-tumor responses—market forces like rising cancer incidence and immunotherapy breakthroughs (e.g., checkpoint inhibitors) favor platforms like MyT™.[2] It influences the ecosystem by validating *in vivo*-optimized TCRs, potentially setting standards for next-gen cell therapies and drawing investment to European biopharma hubs like Berlin.[1][5]
T-knife's near-term catalysts include TK-6302's CTA filing (Q4 2025) and Phase 1 start (2026), with MyT™ expanding the pipeline to more targets via computational *in vivo* screening.[2] Trends like AI-driven antigen discovery and combination regimens will shape its path, amplifying TCR-T's edge in immuno-oncology. Influence may grow through clinical proof-of-concept, partnerships, or acquisitions, solidifying its role in transforming solid-tumor treatment as supercharged therapies prove transformative.[1][3] This positions T-knife at the vanguard of cancer innovation, echoing its founding mission to deliver broad, deep responses.
